Australia - English - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - glucose, quantity: 37.5 g/l; sodium chloride, quantity: 2.25 g/l - injection, solution - excipient ingredients: water for injections - sodium chloride (%) and glucose (%) intravenous infusion is indicated for replenishing fluid losses, as an energy source and for restoration or maintenance of sodium and chloride ion concentrations. it may be used as a vehicle of drug delivery where intravenous delivery is appropriate and the drug is compatible with this solution.

Australia - English - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - glucose, quantity: 33 g/l; sodium chloride, quantity: 3 g/l - injection, solution - excipient ingredients: water for injections - sodium chloride (%) and glucose (%) intravenous infusion is indicated for replenishing fluid losses, as an energy source and for restoration or maintenance of sodium and chloride ion concentrations. it may be used as a vehicle of drug delivery where intravenous delivery is appropriate and the drug is compatible with this solution.

Australia - English - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - glucose, quantity: 25 g/l; sodium chloride, quantity: 4.5 g/l - injection, solution - excipient ingredients: hydrochloric acid; water for injections - sodium chloride (%) and glucose (%) intravenous infusion is indicated for replenishing fluid losses, as an energy source and for restoration or maintenance of sodium and chloride ion concentrations. it may be used as a vehicle of drug delivery where intravenous delivery is appropriate and the drug is compatible with this solution.

Israel - English - Ministry of Health

baxter healthcare distribution ltd., israel - glucose as monohydrate; sodium chloride - solution for infusion - sodium chloride 0.18 %w/v; glucose as monohydrate 4.00 %w/v - electrolytes with carbohydrates - sodium chloride 0.18 % and glucose 4% solution is used in the following indications:dehydration treatment due to a moderated loss of sodium and chloride (vomiting, diarrhoea, renal disorders, overuse ofdiuretics) in cases where a source of energy is required (particularly starvation).paediatric population:this product should only be used in paediatric specialist settings (such as renal, hepatic and cardiac units, highdependency units and intensive care units) for intravenous fluid therapy requiring the use of 0.18% sodium chloride and4% glucose to maintain fluid and electrolyte balance.

Israel - English - Ministry of Health

baxter healthcare distribution ltd., israel - calcium chloride dihydrate; glucose monohydrate (as anhydrous); lactic acid as sodium; magnesium chloride hexahydrate; sodium bicarbonate; sodium chloride - solution for peritoneal dialysis - sodium chloride 5.38 g/l; magnesium chloride hexahydrate 0.051 g/l; lactic acid as sodium 1.68 g/l; sodium bicarbonate 2.10 g/l; glucose monohydrate (as anhydrous) 13.6 g/l; calcium chloride dihydrate 0.184 g/l - sodium chloride - sodium chloride - physioneal is indicated whenever peritoneal dialysis is employed including:acute and chronic renal failure severe water retention severe electrolyte imbalance drug intoxication with dialysable substances when a more adequate therapeutic alternative is not available. bicarbonate/lactate based physioneal peritoneal dialysis solutions with a physiological ph are particularly indicated in patients in whom solutions based on lactate buffer only with a low ph cause abdominal inflow pain or discomfort.

Israel - English - Ministry of Health

baxter healthcare distribution ltd., israel - calcium chloride dihydrate; glucose monohydrate (as anhydrous); lactic acid as sodium; magnesium chloride hexahydrate; sodium bicarbonate; sodium chloride - solution for peritoneal dialysis - sodium chloride 5.38 g/l; glucose monohydrate (as anhydrous) 22.7 g/l; calcium chloride dihydrate 0.184 g/l; lactic acid as sodium 1.68 g/l; magnesium chloride hexahydrate 0.051 g/l; sodium bicarbonate 2.10 g/l - sodium chloride - sodium chloride - physioneal is indicated whenever peritoneal dialysis is employed including:acute and chronic renal failure severe water retention severe electrolyte imbalance drug intoxication with dialysable substances when a more adequate therapeutic alternative is not available. bicarbonate/lactate based physioneal peritoneal dialysis solutions with a physiological ph are particularly indicated in patients in whom solutions based on lactate buffer only with a low ph cause abdominal inflow pain or discomfort.

Australia - English - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - calcium chloride dihydrate, quantity: 67.5 mg; sodium chloride, quantity: 1.5 g; sodium lactate, quantity: 792.5 mg; potassium chloride, quantity: 100 mg - injection, solution - excipient ingredients: water for injections; hydrochloric acid; sodium hydroxide - compound sodium lactate (hartmann's solution) is used:,? for intravenous fluid and electrolyte replacement,? as a source of bicarbonate in the treatment of mild to moderate metabolic acidosis associated with dehydration or associated with potassium deficiency,? as a vehicle for intravenous drug delivery, if the drugs are compatible with the solutions.

United States - English - NLM (National Library of Medicine)

hospira, inc. - sodium chloride (unii: 451w47iq8x) (sodium cation - unii:lyr4m0nh37, chloride ion - unii:q32zn48698), sodium lactate (unii: tu7hw0w0qt) (sodium cation - unii:lyr4m0nh37, lactic acid, unspecified form - unii:33x04xa5at), potassium chloride (unii: 660yq98i10) (potassium cation - unii:295o53k152, chloride ion - unii:q32zn48698), calcium chloride (unii: m4i0d6vv5m) (calcium cation - unii:2m83c4r6zb, chloride ion - unii:q32zn48698), dextrose monohydrate (unii: lx22yl083g) (anhydrous dextrose - unii:5sl0g7r0 - sodium chloride 600 mg in 100 ml - these solutions are indicated for parenteral replacement of extracellular losses of fluid and electrolytes, with or without minimal carbohydrate calories, as required by the clinical condition of the patient. solutions containing lactate are not for use in the treatment of lactic acidosis. to open:   tear outer wrap at notch and remove solution container. if supplemental medication is desired, follow directions below before preparing for administration. some opacity of the plastic due to moisture absorption during the sterilization process may be observed. this is normal and does not affect the solution quality or safety. the opacity will diminish gradually. to add medication   - prepare additive port. - using aseptic technique and an additive delivery needle of appropriate length, puncture resealable additive port at target area, inner diaphragm and inject. withdraw needle after injecting medication. - the additive port may be protected by covering with an additive cap. - mix container contents thoroughly.

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

baxter healthcare (malaysia) sdn. bhd. - icodextrin; calcium chloride ph eur; magnesium chloride ph eur; sodium lactate usp; sodium chloride ph eur -

United States - English - NLM (National Library of Medicine)

baxter healthcare corporation - icodextrin (unii: 2nx48z0a9g) (icodextrin - unii:2nx48z0a9g), sodium chloride (unii: 451w47iq8x) (sodium cation - unii:lyr4m0nh37, chloride ion - unii:q32zn48698), sodium lactate (unii: tu7hw0w0qt) (sodium cation - unii:lyr4m0nh37, lactic acid - unii:33x04xa5at), calcium chloride (unii: m4i0d6vv5m) (calcium cation - unii:2m83c4r6zb, chloride ion - unii:q32zn48698), magnesium chloride (unii: 02f3473h9o) (magnesium cation - unii:t6v3lhy838, chloride ion - unii:q32zn48698) - icodextrin 7.5 g in 100 ml - extraneal (icodextrin) is indicated for a single daily exchange for the long (8- to 16- hour) dwell during continuous ambulatory peritoneal dialysis (capd) or automated peritoneal dialysis (apd) for the management of end-stage renal disease. extraneal is also indicated to improve (compared to 4.25% dextrose) long-dwell ultrafiltration and clearance of creatinine and urea nitrogen in patients with high average or greater transport characteristics, as defined using the peritoneal equilibration test (pet) [see clinical pharmacology (12), clinical studies (14)]. extraneal is contraindicated in patients with a known allergy to cornstarch or icodextrin. extraneal is contraindicated in patients with maltose or isomaltose intolerance and in patients with glycogen storage disease. extraneal is contraindicated in patients with severe lactic acidosis. extraneal contains lactate which may contribute to worsening acidosis if conversion to bicarbonate is impaired and may be associated with hyperventilation, lethargy, hypot